FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent
FDA action · OncLive · 2026-11-12. Number 5 in the UrologyWatch Top 5 for November 13, 2026.
FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.
Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.
Source: OncLive
Loading today's edition…